港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

2,262.402

+27.7291.24%

漲家數：7

跌家數：1

平家數：- -

市盈率：- -

高：2,278.270

開：2,235.125

低：2,231.792

收：2,234.673

資料載入中...

上海萊士：SR604注射液進入Ⅱb期臨牀試驗研究

上海萊士(002252.SZ)：SR604注射液進入Ⅱb期臨牀試驗研究

聯環藥業(600513.SH)：LH-1801項目從臨牀試驗成功到最終上市銷售並實現盈利面臨多重關鍵環節的重大不確定性

【恆瑞醫藥(01276.HK)：SHR-2173注射液獲藥物臨牀實驗批准】智通財經APP訊，恆瑞醫藥(01276.HK)

【恆瑞醫藥(01276.HK)附屬獲得國家藥監局核准簽發關於HRS-9821吸入粉霧劑的《藥物臨牀試驗批准通知書》】智通

【博瑞醫藥：噻託溴銨吸入粉霧劑獲藥物臨牀試驗批准】博瑞醫藥公告，控股子公司艾特美（蘇州）醫藥科技有限公司近日收到國家藥監局簽發的《藥物臨牀試驗批准通知書》，同意艾特美噻託溴銨吸入粉霧劑開展用於慢性阻塞性肺疾病（COPD）的臨牀試驗。噻託溴銨吸入粉霧劑2022年至2024年國內銷售額分別為5.55億元、5.22億元、4.93億元。藥品在獲得批准後尚需開展臨牀試驗並經批准後方可生產上市，短期內對公司經營業務不會產生較大影響。

藥明康德(02359)7月8日斥資2000.76萬元回購28.5萬股A股

恆瑞醫藥(600276.SH)：HRS-9821吸入粉霧劑獲得藥物臨牀試驗批准

金斯瑞生物科技07月08日獲主力加倉1288.5萬元

康龍化成07月08日主力淨流入2024.8萬元散户資金拋售

維亞生物07月08日獲主力加倉98.1萬元

中證城鎮消費指數報2041.26點，前十大權重包含藥明康德等

藥明生物(02269)出現大手賣出22.4萬股，成交價$25.75，涉資576.8萬

阿斯达克财经

大行評級｜招銀國際：上調信達生物目標價至102.95港元看好其豐富的創新管線

CRO/CMO概念震盪反彈，美迪西漲停

每日经济新闻

Press Releases藥明康德第二季度股票回購/購買進展更新 Contact Us

大行評級｜建銀國際：上調信達生物目標價至100港元維持“跑贏大市”評級並列為行業首選

泰格醫藥盤中異動股價大漲5.12%

【港股異動 | 康龍化成(03759.HK)漲超3% 國內首台AMS落户寧波公司一體化研發服務平台全面升級】智通財經A

港股異動 | 康龍化成(03759)漲超3% 國內首台AMS落户寧波公司一體化研發服務平台全面升級

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=11"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":2262.4023,"timestamp":1752826113803,"preClose":2234.6729,"halted":0,"volume":111213688,"delay":0,"changeRate":0.012409,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":27.729492,"latestTime":"07-18 16:00:00","open":2235.1245,"high":2278.2698,"low":2231.7915,"amount":2941815006,"amplitude":0.020799,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1753061400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1752802200000,1752811200000],[1752814800000,1752825600000]],"pbRate":2.678209,"peRate":12.781827,"turnoverRate":0.009531,"increases":7,"decrements":1,"flats":0,"marketCap":518184631296,"floatMarketCap":208736877568},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":2278.2698,"amplitude":0.020799,"preClose":2234.6729,"low":2231.7915,"pbRate":"2.678209","latestPrice":2262.4023,"volume":111213688,"delay":0,"open":2235.1245,"prevYearClose":1395.7731,"prevWeekClose":2104.475,"prevMonthClose":1988.255,"prevQuarterClose":1988.255,"fiveDayClose":2104.475,"twentyDayClose":1884.191,"sixtyDayClose":1574.66,"secType":"PLATE","market":"HK","turnoverRate":0.009531,"peRate":12.781827,"marketCap":518184631296,"floatMarketCap":208736877568,"timestamp":1752826113803,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2549458095","title":"上海萊士：SR604注射液進入Ⅱb期臨牀試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2549458095","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549458095?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 18:09","pubTimestamp":1751969396,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","BK1576","BK0188","BK1583","BK0046","03347","002252","BK0196","BK0239","BK0028"],"gpt_icon":0},{"id":"2549545314","title":"上海萊士(002252.SZ)：SR604注射液進入Ⅱb期臨牀試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2549545314","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549545314?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 18:07","pubTimestamp":1751969270,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海莱士 公告，公司近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了IIb期临床试验登记信息，试验名称为：评价SR604注射液在血友病A/B及先天性凝血因子Ⅶ缺乏症患者中的安全性、耐受性、有效性、PK/PD特征的开放、多中心Ⅰ/Ⅱ期临床试验。据公告所示，SR604注射液拟用于血友病A/B及先天性凝血因子Ⅶ缺乏症患者出血的预防治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","002252","BK1141","BK1576","BK0239","03347","BK0046","BK1583","BK0028","BK0196"],"gpt_icon":0},{"id":"2549483335","title":"聯環藥業(600513.SH)：LH-1801項目從臨牀試驗成功到最終上市銷售並實現盈利 面臨多重關鍵環節的重大不確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2549483335","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549483335?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 17:30","pubTimestamp":1751967041,"startTime":"0","endTime":"0","summary":"公司就LH-1801项目相关情况特别提示如下风险：1、临床数据阶段性结论与未来结果的不确定性：LH-1801项目临床试验采用非劣效设计，最终能否实现目标，存在重大不确定性。最终揭盲结果能否达到非劣目标结果、能否成功获得上市批准、以及获批上市后的具体时间均存在重大不确定性。综上所述，LH-1801项目从临床试验成功到最终上市销售并实现盈利，面临多重关键环节的重大不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU0048573561.USD","LU0251142724.SGD","LU1059921491.USD","BK1141","LU0742534661.SGD","BK4588","LU0006061336.USD","03347","LU0251131958.USD","BK4550","BK4585","BK4196","BK0239","BK1576","600513","LH"],"gpt_icon":0},{"id":"2549753512","title":"【恆瑞醫藥(01276.HK)：SHR-2173注射液獲藥物臨牀實驗批准】智通財經APP訊，恆瑞醫藥(01276.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2549753512","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549753512?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 17:00","pubTimestamp":1751965246,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","LU2488822045.USD","01276","LU1997244956.HKD","LU1328615791.USD","BK1141","BK1583","LU1064130708.USD","03347","BK0012","BK0060","BK0196","LU1997245094.SGD","LU1064131003.USD","BK0028","BK1191","BK0188","LU0405327148.USD","BK0239","LU1969619763.USD","LU2148510915.USD","600276","LU2495084118.USD","LU2328871848.SGD","LU1655091616.SGD","LU1997245177.USD","LU0405327494.USD","BK0183"],"gpt_icon":0},{"id":"2549517350","title":"【恆瑞醫藥(01276.HK)附屬獲得國家藥監局核准簽發關於HRS-9821吸入粉霧劑的《藥物臨牀試驗批准通知書》】智通","url":"https://stock-news.laohu8.com/highlight/detail?id=2549517350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549517350?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:58","pubTimestamp":1751965088,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0012","BK0188","LU1655091616.SGD","LU2148510915.USD","600276","01276","LU1997244956.HKD","LU2488822045.USD","BK1583","03347","BK0196","LU1969619763.USD","BK0060","LU1064130708.USD","LU2495084118.USD","BK0239","BK0183","LU0405327148.USD","BK1576","LU0405327494.USD","LU1997245094.SGD","BK1141","BK0028","LU2328871848.SGD","LU1064131003.USD","BK1191","LU1997245177.USD","LU1328615791.USD"],"gpt_icon":0},{"id":"2549514210","title":"【博瑞醫藥：噻託溴銨吸入粉霧劑獲藥物臨牀試驗批准】博瑞醫藥公告，控股子公司艾特美（蘇州）醫藥科技有限公司近日收到國家藥監局簽發的《藥物臨牀試驗批准通知書》，同意艾特美噻託溴銨吸入粉霧劑開展用於慢性阻塞性肺疾病（COPD）的臨牀試驗。噻託溴銨吸入粉霧劑2022年至2024年國內銷售額分別為5.55億元、5.22億元、4.93億元。藥品在獲得批准後尚需開展臨牀試驗並經批准後方可生產上市，短期內對公司經營業務不會產生較大影響。","url":"https://stock-news.laohu8.com/highlight/detail?id=2549514210","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549514210?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:43","pubTimestamp":1751964235,"startTime":"0","endTime":"0","summary":"博瑞医药公告，控股子公司艾特美（苏州）医药科技有限公司近日收到国家药监局签发的《药物临床试验批准通知书》，同意艾特美噻托溴铵吸入粉雾剂开展用于慢性阻塞性肺疾病（COPD）的临床试验。噻托溴铵吸入粉雾剂2022年至2024年国内销售额分别为5.55亿元、5.22亿元、4.93亿元。药品在获得批准后尚需开展临床试验并经批准后方可生产上市，短期内对公司经营业务不会产生较大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/08164351557624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","BK1515","BK1583","03347","BK1574","159938","09939","BK1161","BK1141","688166","BK0239"],"gpt_icon":0},{"id":"2549511128","title":"藥明康德(02359)7月8日斥資2000.76萬元回購28.5萬股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2549511128","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549511128?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:36","pubTimestamp":1751963791,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，该公司于2025年7月8日斥资2000.76万元人民币回购28.5万股A股，每股回购价格为69.64-70.84元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708995583.HKD","LU1997245094.SGD","LU2328871848.SGD","159982","LU2125910500.SGD","LU2045819591.USD","LU0052750758.USD","LU1997245177.USD","BK1583","399300","LU1046422090.SGD","LU2242644610.SGD","603259","LU1969619763.USD","BK1141","LU2495084118.USD","LU1997244956.HKD","02359","LU0456842615.SGD","LU2488822045.USD","BK0216","BK1576","LU0320764599.SGD"],"gpt_icon":0},{"id":"2549519632","title":"恆瑞醫藥(600276.SH)：HRS-9821吸入粉霧劑獲得藥物臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2549519632","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549519632?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:19","pubTimestamp":1751962755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局核准签发关于HRS-9821吸入粉雾剂的《药物临床试验批准通知书》，将于近期开展临床试验。据悉，HRS-9821是小分子PDE3/PDE4 抑制剂，可有效抑制呼吸道炎症、扩张支气管，临床拟用于COPD的维持治疗。目前全球同类产品仅Ensifentrine于2024 年7月在美国获批上市，用于COPD的维持治疗。截至目前，HRS-9821相关项目累计研发投入约3,843万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0405327494.USD","600276","LU1328615791.USD","BK1141","BK1583","LU1655091616.SGD","03347","LU1064130708.USD","01276","LU1997245094.SGD","BK0012","BK0196","LU1997245177.USD","BK0183","LU1997244956.HKD","BK0028","BK0188","LU1969619763.USD","BK0239","LU2495084118.USD","LU1064131003.USD","LU2488822045.USD","BK1191","BK1576","LU2328871848.SGD","BK0060","LU2148510915.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2549358510","title":"金斯瑞生物科技07月08日獲主力加倉1288.5萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549358510","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549358510?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:16","pubTimestamp":1751962563,"startTime":"0","endTime":"0","summary":"07月08日, 金斯瑞生物科技股价涨1.37%，报收14.84元，成交金额2.2亿元，换手率0.69%，振幅4.23%，量比0.71。金斯瑞生物科技今日主力资金净流入1288.5万元，连续3日净流入，上一交易日主力净流入767.1万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为50.00%，平均涨幅为3.34%。该股近5个交易日上涨0.68%，主力资金累计净流入1348.9万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出1.8亿元，其中净流出天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170348a69ccd91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170348a69ccd91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","01548","BK1576","HK0000320223.HKD","HK0000320264.USD","HK0000306701.USD","BK1583","BK1141"],"gpt_icon":0},{"id":"2549489145","title":"康龍化成07月08日主力淨流入2024.8萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2549489145","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549489145?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:16","pubTimestamp":1751962560,"startTime":"0","endTime":"0","summary":"07月08日, 康龙化成股价涨3.40%，报收17.02元，成交金额1.5亿元，换手率2.95%，振幅4.86%，量比1.45。康龙化成今日主力资金净流入2024.8万元，上一交易日主力净流出899.6万元。该股近5个交易日上涨4.15%，主力资金累计净流入1191.1万元；近20日主力资金累计净流出913.7万元，其中净流出天数为13日。该股主力净额占比0.40%，港股市场排名30/2669。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170248a69cccce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708170248a69cccce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","03759","BK1141"],"gpt_icon":0},{"id":"2549512937","title":"維亞生物07月08日獲主力加倉98.1萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549512937","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549512937?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 16:15","pubTimestamp":1751962542,"startTime":"0","endTime":"0","summary":"07月08日, 维亚生物股价涨4.35%，报收1.44元，成交金额1016.1万元，换手率0.33%，振幅6.52%，量比0.85。维亚生物今日主力资金净流入98.1万元，连续3日净流入，上一交易日主力净流入26.7万元。该股近5个交易日下跌4.55%，主力资金累计净流出208.0万元；近20日主力资金累计净流出1017.9万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165615a69cc89e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165615a69cc89e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01873","BK1576","BK1141"],"gpt_icon":0},{"id":"2549196805","title":"中證城鎮消費指數報2041.26點，前十大權重包含藥明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2549196805","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549196805?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 15:59","pubTimestamp":1751961553,"startTime":"0","endTime":"0","summary":"金融界7月8日消息，上证指数高开高走，中证城镇消费指数 报2041.26点。数据统计显示，中证城镇消费指数近一个月下跌1.48%，近三个月上涨4.15%，年至今下跌3.00%。该指数以2012年06月29日为基日，以1000.0点为基点。从中证城镇消费指数持仓样本的行业来看，可选消费占比30.50%、主要消费占比29.57%、医药卫生占比22.96%、信息技术占比13.99%、通信服务占比2.99%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708160311979e0f05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708160311979e0f05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","LU0320764599.SGD","LU1046422090.SGD","BK1576","LU2125910500.SGD","02359","LU0052750758.USD","LU0708995583.HKD","LU2045819591.USD","BK1583","LU2242644610.SGD"],"gpt_icon":0},{"id":"2549597639","title":"藥明生物(02269)出現大手賣出22.4萬股，成交價$25.75，涉資576.8萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2549597639","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549597639?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 14:10","pubTimestamp":1751955000,"startTime":"0","endTime":"0","summary":"[大手成交]药明生物(02269)在下午02:10出现大手卖出，成交量为22.4万，成交价为港币$25.75，涉资576.8万。至目前为止，股价升2.794%，今日最高价为$25.8，而最低价为$24.65，总成交量为2.854千万股，总成交金额港币$7.184亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2507085584/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1242518857.USD","SG9999002562.SGD","LU0708995583.HKD","LU0140636845.USD","LU0359201612.USD","02269","LU0348735423.USD","LU0819121731.USD","LU1880383366.USD","LU0823426308.USD","LU0456827905.SGD","LU0516423174.USD","SG9999002463.SGD","LU0320764599.SGD","LU0417516902.SGD","LU1242518931.SGD","LU0051755006.USD","LU0043850808.USD","LU0979878070.USD","BK1589","LU0181495838.USD","BK1610","LU0823426480.USD","LU0417516738.SGD","LU2039709279.SGD","LU0327786744.USD","LU0456846285.SGD","IE00B0JY6N72.USD","LU0359202008.SGD","LU0516422366.SGD","LU0572944931.SGD","LU0326950275.SGD","LU0516422952.EUR","LU1688375341.USD","LU1720050803.USD","LU1794554557.SGD","BK1141","LU0039217434.USD","LU0856984785.SGD","LU0588546209.SGD","LU0307460666.USD","LU0052750758.USD","LU0348825331.USD","LU0516423091.SGD","BK1576","BK1521","LU0516422440.USD"],"gpt_icon":0},{"id":"2549596551","title":"大行評級｜招銀國際：上調信達生物目標價至102.95港元 看好其豐富的創新管線","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596551","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549596551?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 11:46","pubTimestamp":1751946396,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","BK1589","01801","03347","BK1583","BK4023","LU2488822045.USD","LU2328871848.SGD","GLP","BK7095","ADC.AU","BK1576","BK4144","LU1969619763.USD","BK4590","PD","BK1161","BK4080","ADC","BK4231","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2549595215","title":"CRO/CMO概念震盪反彈，美迪西漲停","url":"https://stock-news.laohu8.com/highlight/detail?id=2549595215","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549595215?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 11:23","pubTimestamp":1751945013,"startTime":"0","endTime":"0","summary":"7月8日，CRO/CMO概念震荡反弹，美迪西涨停，昭衍新药、华测检测、益诺思、泰格医药、诺思格、和元生物等跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507083450862638.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507083450862638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1576","BK1141","03347","06127"],"gpt_icon":0},{"id":"2549730593","title":"Press Releases藥明康德第二季度股票回購/購買進展更新 Contact Us","url":"https://stock-news.laohu8.com/highlight/detail?id=2549730593","media":"动脉网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549730593?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 10:45","pubTimestamp":1751942700,"startTime":"0","endTime":"0","summary":"药明康德更新2025年第二季度股票回购进展，完成10亿元人民币A股回购及25亿港元H股购买，以提升股东价值和吸引人才。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708104724979dc5a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708104724979dc5a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0708995583.HKD","LU0052750758.USD","BK1583","603259","LU1046422090.SGD","02359","LU2242644610.SGD","BK1576","LU2125910500.SGD","LU2045819591.USD","LU0320764599.SGD","BK1141"],"gpt_icon":0},{"id":"2549980455","title":"大行評級｜建銀國際：上調信達生物目標價至100港元 維持“跑贏大市”評級並列為行業首選","url":"https://stock-news.laohu8.com/highlight/detail?id=2549980455","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549980455?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 10:41","pubTimestamp":1751942504,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["ADC","03347","BK1589","ADC.AU","LU1969619763.USD","BK1576","LU2488822045.USD","BK4080","BK7095","BK1161","BK4231","01801","LU2328871848.SGD","BK1583","BK1141"],"gpt_icon":0},{"id":"2549983775","title":"泰格醫藥盤中異動 股價大漲5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549983775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549983775?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 10:03","pubTimestamp":1751940198,"startTime":"0","endTime":"0","summary":"2025年07月08日早盘10时03分，泰格医药股票出现异动，股价急速拉升5.12%。截至发稿，该股报41.100港元/股，成交量107.48万股，换手率0.87%，振幅5.88%。泰格医药股票所在的生物技术行业中，整体涨幅为0.34%。其相关个股中，正大企业国际、华康生物医学、昭衍新药涨幅较大，振幅较大的相关个股有基石药业-B、北海康成-B、正大企业国际，振幅分别为18.57%、16.28%、12.44%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708100318a69c06ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708100318a69c06ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2549956725","title":"【港股異動 | 康龍化成(03759.HK)漲超3% 國內首台AMS落户寧波 公司一體化研發服務平台全面升級】智通財經A","url":"https://stock-news.laohu8.com/highlight/detail?id=2549956725","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549956725?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 09:44","pubTimestamp":1751939041,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","BK6515","M11.SI","AMS","03759","BK4196","BK0216","BK1141","300759","BK6062"],"gpt_icon":0},{"id":"2549567254","title":"港股異動 | 康龍化成(03759)漲超3% 國內首台AMS落户寧波 公司一體化研發服務平台全面升級","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567254","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549567254?lang=zh_tw&edition=fundamental","pubTime":"2025-07-08 09:44","pubTimestamp":1751939041,"startTime":"0","endTime":"0","summary":"消息面上，据康龙化成官微消息，7月7日，康龙化成宣布，中国首台应用于新药研发的低能耗加速器质谱在宁波完成安装调试，助力公司进一步提升放射性同位素高灵敏度、微量示踪药物代谢和生物分析服务能力。此次最新一代的高通量AMS落户宁波，标志着公司“放射性同位素药物标记合成-临床研究-分析检测”一体化研发服务平台的全面升级，助力公司技术实力持续领跑全球，为客户提供更高效、更精准、更灵活的解决方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AMS","BK1141","BK0216","03759","BK1576","BK4196","300759"],"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":11,"totalSize":246,"code":"91000000","status":"200"}]}}